menu
    • menu
    [{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Enterome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symbiosis Pharmaceutical Services","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"7","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Clene Nanomedicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Enema","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Paradox Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"LX-96","moa":"IgG","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Symbiosis Pharmaceutical Services","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"4","companyTruncated":"Symbiosis Pharmaceutical Services \/ Symbiosis Pharmaceutical Services"}]

    Find Clinical Drug Pipeline Developments & Deals by Symbiosis Pharmaceutical Services

    Menu

    Symbiosis Pharmaceutical Services

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX-96

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Paradox Immunotherapeutics

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Paradox Gets $10M from SymBiosis to Advance Protein Misfolding Disease Therapies

                            Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 25, 2025

                            Lead Product(s) : LX-96

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Paradox Immunotherapeutics

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Recipient : Clene Nanomedicine

                            Deal Size : $7.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Clene Closes $7.3M Offering and Amends Debt Facility for Ongoing Initiatives

                            Details : The proceeds will be used to file a new drug application under the accelerated approval pathway for CNM-Au8, a catalytically active gold nanocrystal suspension.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            January 10, 2024

                            Lead Product(s) : CNM-Au8

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Clene Nanomedicine

                            Deal Size : $7.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EO2401,Bevacizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Enterome

                            Deal Size : $52.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Enterome Completes €46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Thera...

                            Details : Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 25, 2020

                            Lead Product(s) : EO2401,Bevacizumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Enterome

                            Deal Size : $52.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ChAdOx1 nCoV-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture

                            Details : Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : ChAdOx1 nCoV-19

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed

                            Symbiosis Pharmaceutical Services

                            United Kingdom arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MaaT013

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : MaaT Pharma

                            Deal Size : $19.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            MaaT Pharma Announces €18 Million Series B Financing

                            Details : The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 02, 2020

                            Lead Product(s) : MaaT013

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : MaaT Pharma

                            Deal Size : $19.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth